Veracyte, Inc.
VCYT
$43.34
-4.22%
Veracyte, Inc. is a genomic diagnostics company that provides advanced diagnostic tests for various cancers, including prostate (Decipher Prostate), thyroid (Afirma), breast (Prosigna), and bladder (Decipher Bladder). The company operates in the healthcare sector, specifically within the medical diagnostics and research industry, and is recognized for its innovative genomic tests that guide clinicians in cancer diagnosis and treatment decisions. Veracyte is a niche player in the precision oncology space, leveraging its proprietary genomic platforms to differentiate itself from traditional diagnostic companies. The current investor narrative centers on the company's strong revenue growth and expanding test adoption, but recent stock volatility and a significant pullback from its 52-week high have raised questions about valuation sustainability and competitive pressures. Investors are closely watching the company's ability to maintain its growth trajectory amid a broader market selloff and potential reimbursement challenges.…
VCYT
Veracyte, Inc.
$43.34
Related headlines
Investment Opinion: Should I buy VCYT Today?
Based on the analysis, VCYT is rated a Buy. The thesis is that Veracyte's strong revenue growth, high gross margins, and attractive valuation relative to growth (PEG 0.31) provide a favorable risk/reward. The analyst consensus of 'buy' with an average target of $57.82 supports this view, implying a +40.2% upside. Key supporting data points include: forward PE of 21.17x, estimated EPS growth to $2.39, gross margin of 69.62%, and a 1-year price change of +37.32% outperforming the market. However, the rating is conditional on sustained growth; if revenue growth falls below 15% or the forward PE exceeds 30x, the thesis would weaken. The stock is currently fairly valued relative to its growth, but the recent pullback offers an attractive entry point.
Sign up to view all
VCYT 12-Month Price Forecast
The AI assessment leans bullish, driven by strong fundamental growth and a reasonable valuation relative to growth. The recent pullback of -30.68% in the past month appears overdone, given the company's solid fundamentals. However, the high beta of 1.94 and wide analyst target range suggest uncertainty. The stance would be upgraded to high confidence if the next earnings report shows accelerating revenue growth and if the stock stabilizes above $35. Conversely, a downgrade to neutral would occur if growth decelerates or if the stock breaks below its 52-week low.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Veracyte, Inc.'s 12-month outlook, with a consensus price target around $57.82 and implied upside of +33.4% versus the current price.
Average Target
$57.82
0 analysts
Implied Upside
+33.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$44 - $70
Analyst target range
Veracyte is covered by 11 analysts, with a consensus recommendation of 'buy' and a mean recommendation score of 1.67 (where 1 is strong buy and 5 is sell). The average target price is $57.82, implying an upside of approximately +40.2% from the current price of $41.25. The target price range is $44.00 (low) to $70.00 (high), indicating a wide spread of 59.1% between the low and high targets, which reflects high uncertainty about the company's future performance. The high target of $70.00 suggests that some analysts expect strong growth and multiple expansion, while the low target of $44.00 implies a more conservative outlook, possibly factoring in competitive risks or margin pressures. The consensus leans bullish, but the wide target range and recent price volatility suggest that investors should approach with caution. The estimated EPS for the next fiscal year is $2.39, which would put the forward PE at approximately 17.3x based on the current price, further supporting the bullish case.
Bulls vs Bears: VCYT Investment Factors
Veracyte presents a compelling growth story with strong revenue expansion, high gross margins, and a bullish analyst consensus. However, the recent -30.68% monthly decline and high beta of 1.94 highlight significant volatility and risk. The bull case is currently stronger, supported by a PEG ratio of 0.31 and a forward PE of 21.17x, suggesting the stock is undervalued relative to its growth potential. The most critical tension is whether the recent pullback is a temporary correction or the start of a trend reversal, which will depend on the company's ability to sustain growth and manage competitive pressures. If growth continues, the stock could re-rate higher, but any disappointment could lead to further downside.
Bullish
- Strong Revenue Growth: Veracyte's estimated annualized revenue of $935.96 million reflects robust growth, with a 1-year price change of +37.32% outperforming the S&P 500's +20.37%. This indicates strong adoption of its genomic tests across multiple cancer types.
- High Gross Margin: The company boasts a gross margin of 69.62%, well above industry norms, indicating strong pricing power and efficient cost management. This supports profitability and reinvestment in growth initiatives.
- Attractive PEG Ratio: With a PEG ratio of 0.31, the stock appears undervalued relative to its growth prospects. The forward PE of 21.17x is near the lower end of its historical range, suggesting the market may be underpricing future earnings growth.
- Bullish Analyst Consensus: Analysts rate VCYT as a 'buy' with a mean recommendation score of 1.67 (1=strong buy). The average target price of $57.82 implies a +40.2% upside from the current price of $41.25, reflecting confidence in the company's growth trajectory.
Bearish
- Recent Sharp Pullback: The stock has fallen -30.68% in the past month, significantly underperforming the S&P 500's +2.85% gain. This suggests potential negative sentiment or profit-taking after a strong run, raising concerns about near-term momentum.
- High Valuation Premium: The PS ratio of 6.40x is higher than the sector median, indicating a premium valuation. If growth decelerates, the stock could face multiple compression, leading to significant downside.
- High Volatility: With a beta of 1.94, VCYT is nearly twice as volatile as the market. This amplifies both gains and losses, making it a risky investment for risk-averse investors, especially in uncertain market conditions.
- Wide Analyst Target Range: The analyst target price range spans from $44.00 to $70.00, a 59.1% spread. This wide dispersion indicates high uncertainty about the company's future performance, which could lead to erratic price movements.
VCYT Technical Analysis
Veracyte's stock has exhibited a strong uptrend over the past year, with a 1-year price change of +37.32%, significantly outperforming the S&P 500's +20.37% over the same period. The current price of $41.25 sits at approximately 67.7% of its 52-week range (calculated as (41.25 - 28.25) / (60.91 - 28.25) = 0.404, or 40.4% from the low to the high, but relative to the range, it is 40.4% above the low and 32.3% below the high). This positioning suggests the stock has pulled back from its highs but remains well above its lows, indicating a potential consolidation phase after a strong rally. The stock's beta of 1.94 implies it is nearly twice as volatile as the market, which is crucial for risk management.
Beta
1.94
1.94x market volatility
Max Drawdown
-39.2%
Largest decline past year
52-Week Range
$29-$61
Price range past year
Annual Return
+44.7%
Cumulative gain past year
| Period | VCYT Return | S&P 500 |
|---|---|---|
| 1m | -22.2% | +5.5% |
| 3m | -6.5% | +1.7% |
| 6m | +18.4% | +12.2% |
| 1y | +44.7% | +18.6% |
| ytd | +2.2% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VCYT Fundamental Analysis
Veracyte's revenue growth has been robust, with the latest quarterly revenue estimated at $935.96 million (annualized estimate), reflecting a strong growth trajectory. The company's net margin of 12.83% and gross margin of 69.62% indicate solid profitability and pricing power. Over the past year, the company has demonstrated consistent growth, with a 1-year price change of +37.32% and a 6-month change of +15.32%, suggesting accelerating momentum. However, the 1-month price change of -30.68% indicates a sharp recent pullback, which could signal a short-term correction or a potential trend reversal. The stock's relative strength versus the S&P 500 over the past month is -33.53%, showing significant underperformance, while its 3-month relative strength is +2.17%, indicating longer-term outperformance. This divergence suggests that the recent decline may be a temporary setback rather than a fundamental deterioration, but investors should monitor for further weakness.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VCYT Overvalued?
Given that Veracyte has positive net income (EPS of $0.02), the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 50.12x, while the forward PE is 21.17x, implying that the market expects significant earnings growth. The gap between trailing and forward PE suggests that analysts anticipate a substantial increase in earnings, which is supported by the PEG ratio of 0.31, indicating that the stock may be undervalued relative to its growth prospects. Compared to the industry average, Veracyte's PS ratio of 6.40x is higher than the sector median, reflecting a premium valuation. However, this premium may be justified by the company's strong gross margin of 69.62% and operating margin of 14.34%, which are above industry norms. Historically, Veracyte's valuation has been volatile, but the current forward PE of 21.17x is near the lower end of its historical range, suggesting that the stock may be trading at a reasonable valuation relative to its growth potential.
PE
50.1x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Veracyte carries minimal debt (debt-to-equity of 0.03) and has a strong current ratio of 8.15, indicating ample liquidity. However, the company's reliance on continued revenue growth to justify its valuation is a key risk; if growth decelerates, the high PS ratio of 6.40x could compress, leading to a significant de-rating. Additionally, the net margin of 12.83% is relatively thin, leaving little room for cost pressures or pricing concessions. The company's cash flow is positive (PCF ratio of 24.27x), but any unexpected increase in operating expenses could strain profitability.
FAQ
The key risks of holding VCYT include: 1) Financial risk: The company's thin net margin of 12.83% leaves little room for cost pressures, and its reliance on growth to justify valuation could lead to volatility. 2) Competitive risk: The diagnostics market is competitive, and a rival could launch a superior test, eroding market share. 3) Macro risk: With a beta of 1.94, the stock is highly sensitive to market movements, and a downturn could amplify losses. 4) Regulatory risk: Changes in reimbursement policies could directly impact revenue. The most severe risk is a combination of these factors leading to a decline to the 52-week low of $28.25, representing a -31.5% downside from the current price.
The 12-month forecast for VCYT is bullish, with a base case target of $57.82 (analyst average), implying a +40.2% upside. The bull case target is $70.00 (analyst high), with a 35% probability, while the bear case target is $44.00 (analyst low), with a 20% probability. The base case, with a 45% probability, assumes continued revenue growth and stable margins. The most likely scenario is the base case, driven by strong adoption of its genomic tests and a favorable reimbursement environment. Investors should monitor quarterly earnings for signs of growth acceleration or deceleration, which would shift the probabilities.
Based on the data, VCYT appears undervalued relative to its growth prospects. The trailing PE of 50.12x is high, but the forward PE of 21.17x indicates that the market expects substantial earnings growth. The PEG ratio of 0.31 is well below 1, suggesting the stock is undervalued relative to its growth rate. Compared to the industry, the PS ratio of 6.40x is above the sector median, indicating a premium, but this is justified by the company's high gross margin of 69.62%. Historically, the forward PE is near the lower end of its range, suggesting the stock is trading at a reasonable valuation. The market is pricing in strong growth, but if growth meets expectations, the stock could re-rate higher.
VCYT appears to be a good buy for investors with a growth-oriented, risk-tolerant profile. The stock has a forward PE of 21.17x, which is reasonable given its estimated EPS growth to $2.39, and a PEG ratio of 0.31, suggesting undervaluation. Analyst consensus is 'buy' with an average target of $57.82, implying a +40.2% upside. However, the recent -30.68% monthly decline and high beta of 1.94 indicate significant volatility, so investors should be prepared for price swings. The biggest downside risk is a failure to sustain growth, which could lead to multiple compression. Overall, it is a good buy for those who believe in the company's growth story and can tolerate short-term fluctuations.
VCYT is better suited for long-term investment, given its growth stage and high volatility (beta of 1.94). The company is in a growth phase with strong revenue expansion, but short-term price movements can be erratic, as seen in the -30.68% monthly decline. Long-term investors can benefit from the company's potential to capitalize on the growing precision oncology market, with a suggested minimum holding period of 3-5 years to ride out volatility. Short-term trading is possible but risky due to the high beta and wide analyst target range. The company pays no dividend, so returns are entirely dependent on capital appreciation, which favors a longer horizon.